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The role of lipid peroxidation in the mechanism of arsenic toxicity was investigated in female rats pretreated with N-acetylcysteine (NAC, a glu-
tathione [GSHI inducer) or with buthionine sulfoximine (BSO, a GSH depletor). Rats were challenged with sodium arsenite, and sacrificed 1 hr after
this treatment. Results showed that arsenic decreased GSH levels and increased lipid peroxidation in liver, kidney, and heart, with a larger effect at
18.2 mg/kg than at 14.8 mg/kg for lipid peroxidation induction. In the liver of rats treated with arsenic, pretreatment with NAC increased the levels of
GSH and decreased lipid peroxidation. In kidney and heart, NAC pretreatment protected the tissues against arsenic-induced depletion of GSH lev-
els,but the same degree of protection was not found for lipid peroxidation induction. In its turn, BSO had an additive effect with arsenic in lowering
the levels of GSH in the liver and kidney, but an inverse correlation between GSH levels and lipid peroxidation was found only in liver. Arsenic con-
tent in tissues of rats pretreated with NAC was lower than in rats treated only with arsenic. In rats with depleted levels of GSH (BSO-pretreated
rats), a shift in arsenic tissue distribution was found, with higher levels in skin and lower levels in kidney. A clear tendency for a positive correlation
between arsenic concentration and lipid peroxidation levels was found in liver, kidney, and heart. - Environ Health Perspect 103(Suppl 1):85-88
(1995)
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Introduction
Arsenic is a naturally occurring element
that has been recognized as a human poi-
son since ancient times. Inorganic arsenic is
known to cause skin cancer after ingestion
and lung cancer after inhalation (1).
Recently, it has been suggested that
ingested arsenic also causes cancers of the
bladder, kidney, lung, and liver (2). In the
environment near copper and zinc
smelters, arsenic occurs together with other
metals, such as cadmium and lead (3).
Therefore, it becomes important to study
the coexposure to these metals, including
the cellular defense mechanisms used
against them.
Previously, we have shown that the
mixture of As+ Cd is more toxic than
either arsenic or cadmium alone (4,5).
However, in testes of rats treated with
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As+Cd, a 37% increase in glutathione
(GSH) content was related to protection
against cadmium-induced morphologic
changes (4). Furthermore, in heart tissue
of rats treated with As+Cd, an increase in
arsenic content was related to an increase
in GSH (5). In searching for a possible
mechanism ofthe arsenic-cadmium inter-
action in rats, these results prompted us to
study further the relationship between
GSH and arsenic toxicity.
Studies in vivo and in vitro have con-
cluded that GSH may play a role in arsenic
detoxification through different mecha-
nisms: facilitation ofits uptake by the cells
(6), modulation of the first methylation
reaction (7), and stimulation of the excre-
tion ofdimethylarsinic acid (6). Further-
more, it has been shown that GSH
participates in the biliary excretion of
arsenic (8). In agreement with these
results, it has also been shown that GSH
levels and GSH-S-transferase activity were
increased in arsenic-resistant Chinese ham-
ster ovary cells (9), and that in asynchro-
nous human fibroblasts GI phase (10), in
asynchronous Chinese hamster ovary cells
(10), or in endothelial cells pretreated with
GSH (11), the intracellular level ofGSH is
inversely correlated with the cytotoxic
effect ofarsenic.
Conversely, it has been reported that
arsenic toxicity was potentiated after pre-
treatment with drugs that produced GSH
depletion (12). This enhancement of
arsenic-induced injury in GSH-depleted
animals, may result from impaired methyl-
ation. Pretreatment with depletors ofGSH
levels in hamsters (12), rat (13), and rat
tissue slices (6), impaired the methylation
ofinorganic arsenic. It has been shown that
methylation renders arsenic less reactive
with tissue and therefore facilitates its elim-
ination from the body (14). Arsenic tissue
accumulation has been demonstrated in
blood, liver, and kidney of hamsters pre-
treated with BSO (12), and in liver of rats
pretreated with phorone (a depletor of
GSH concentrations) (13).
The relationship between arsenic tissue
levels and GSH levels seems to be clear.
However, because glutathione is also a part
of a cellular defense mechanism against
peroxidative attacks, the role oflipid perox-
idation as a mechanism of arsenic toxicity
remains to be investigated. In the present
work, this subject was investigated in
female rats pretreated with N-acetylcysteine
(a GSH inducer) or with buthionine sul-
foximine (a GSH depletor), and challenged
with different concentrations of sodium
arsenite.
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Materials and Methods
Animals
Wistar strain female rats (200-225 g) were
allowed free access to food (Laboratory
rodent diet, St. Louis, MO) and water.
Buthionine Sulfoximine or
N-Acetyl-L-cysteine Admnistraion
Buthionine sulfoximine (BSO) is an agent
that depletes GSH by inhibiting the
enzyme glutamylcysteine synthetase (15),
whereas N-acetyl-L-cysteine (NAG) stimu-
lates GSH synthesis by providing higher
than normal concentrations of L-cysteine
(16). Animals were injected sc with BSO
(0.89 g/kg), and NAC was administered po
(1.2 g/kg). At different times posttreat-
ment, groups of six animals each were
sacrificed and GSH levels were quantified
in the liver. When compared to a saline-
treated group, the maximum depletion of
GSH by BSO was found to be 60% at 4 hr
posttreatment (p < 0.001) and remained at
this level during 2 hr. When compared to a
saline-treated group, the maximum induc-
tion of GSH by NAC was found to be
40% at 60 min posttreatment (p< 0.001)
and remained at this level during 1 hr.
Arsenic Adnistraton
It was ofinterest to examine if the arsenic
toxicity could be enhanced by GSH deple-
tion. The effect ofdecreased GSH concen-
trations on arsenic-induced injury was
studied in rats pretreated with BSO and
challenged with sodium arsenite ip at a
nonlethal dose (LDO). Also, to investigate
the possible attenuation of arsenic toxicity
by increased levels ofGSH, rats were pre-
treated with NAC and challenged with
sodium arsenite ip at a lethal dose
(LD100).
To calculate the LDO and the LD100, a
dose-response determination was per-
formed. Determinations were carried out
using five doses ofsodium arsenite injected
intraperitoneally. Groups ofeight animals
were employed for each dose. Animals
were observed frequently during normal
working hours. For the LDO and LD100
calculations, the numbers of deaths in 24
hr, 48 hr, and 72 hr were recorded, data
were evaluated by probit analysis, and
confidence limits were calculated (17).
For all experiments, 14.8 mg/kg of
arsenic (AsO), which is a dose within the
95% confidence limits for the LDO, was
administered 4 hr after the treatment with
BSO; 18.2 mg/kg of arsenic (As100),
which is a dose within the 95% confidence
limits for the LD100, was given 1 hr after
NAC treatment.
In order to observe the effect ofarsenic
during the time of maximum effect either
ofNAC or BSO, animals were sacrificed
by cervical dislocation 1 hr after the arsenic
challenge. For studying the effects of
administering BSO or NAC alone, saline
was given in place ofarsenic. For studying
the effects ofarsenic alone, saline was given
in place ofBSO or NAC.
BiochemicalAnalysis
All operations were done at 4°C. Animals
were sacrificed by cervical dislocation 1 hr
after the challenge either with arsenic or
saline. Tissues were immediately perfused
with cooled buffer that contained 0.9%
KCl, pH 7.2. They were homogenized in 9
vol of 1.15% KCl, 125 mM sucrose, pH
7.2. The homogenates were employed for
the assays. Lipid peroxidation was deter-
mined by measuring the amounts of thio-
barbiturate-reactive substances (TBA-RS)
according to the method ofOhkawa et al.
(18). Using 1,1,3,3,-tetramethoxypropane
(TMP) as an external standard, the levels
ofthe TBA-RS were expressed as nmole of
TMP/g of tissue. Glutathione levels were
determined as nonprotein soluble thiols, as
previously described (4).
ArsenicAnalysis
Arsenic analyses were performed using a
Perkin-Elmer model 2380 atomic absorp-
tion spectrophotometer. Tissue samples
were placed in acid-washed glass test tubes
and solubilized with a mixture of nitric,
perchloric, and sulfuric acids, for at least 9
hr. Arsenic was determined by hydride evo-
lution-atomic absorption technique. As an
internal quality control, blind random sam-
ples ofNIST standard reference material
SRM-1577a (bovine liver) were analyzed.
For arsenic, recoverywas 94%.
Results
In liver, AsO and As100 increased the level
oflipid peroxidation and a correlation with
the doses was observed. Arsenic also
depleted GSH; however, in this case the
relationship to the doses was not evident
because the results with 18.2 mg/kg
(As1OO) were not significantly different
from those with 14.8 mg/kg (AsO) (Table
1). Rats pretreated with NAC and chal-
lenged with AsiO1 also showed a
significant increase in lipid peroxidation
and a depletion in GSH levels when com-
pared to a control group (NAC-saline
treatment). Similar results were obtained in
Table 1. Lipid peroxidation and glutathione levels in
liver of rats pretreated with N-acetylcysteine or buthio-
nine sulfoximine and subsequently challenged with
arsenic.
Peroxidation, Glutathione,
Treatment nmole TMP/g tissue pmole/g tissue
Saline-saline 349.15 (46.88) 3.49 (0.13)
Saline-AsO 598.59 (73.61(a 1.85(0.14)a
Saline-AslOD 807.08(82.44)a 1.68(0.20)a
NAC-saline 409.84 (61.25) 5.23 (0.16)
NAC-AslOO 567.31 (70.34)c 2.20 (0.53)c
BSO-saline 528.79 (35.58) 1.18 (0.19)
BSO-AsO 692.90 (83.46) 0.64 (0.17)
Rats were pretreated with NAC (1.2 g/kg, po) and chal-
lenged with sodium arsenite (As1OO 18.2 mg/kg, ip) 1
hr after the treatment with NAC; or were pretreated
with BSO (0.89 g/kg, sc) and challenged with sodium
arsenite (AsO 14.8 mg/kg, ip) 4 hr after the treatment
with BSO. Control rats were pretreated and challenged
with saline. Rats were sacrificed 1 hr after the treat-
ment with arsenic. aDifferent from control p<0.001.
bDifferent from AsO p<0.001. CDifferent from NAC
p<0.001. dDifferent from BSO p<0.001. Results are
mean values obtained from six animals in each treat-
ment group. Standard deviation is given in parenthe-
ses. Data were evaluated by the Student-Newman-
Keuls test.
the BSO-AsO rats, compared to rats
treated onlywith BSO (Table 1).
In the kidney, AsO and As1OO increased
lipid peroxidation and this increase was
inversely related to GSH levels (Table 2).
In rats pretreated with NAC, As10O induced
lipid peroxidation; however, GSH levels
were similar to those in NAC-saline-treated
rats. The opposite effect, depletion ofGSH
levels without a change in lipid peroxida-
tion, was observed in rats pretreated with
BSO and treated with AsO, compared to
rats treated onlywith BSO (Table 2).
Results in the heart are shown in Table
3. It can be observed again that AsO and
As100 increased lipid peroxidation,
whereas only As100 decreased GSH levels.
Rats pretreated with either NAC or BSO
and challenged with arsenic did not show a
decrease in GSH levels; however, in both
types ofpretreatment, arsenic induced an
increase in lipid peroxidation.
Arsenic tissue levels were also investi-
gated (Table 4). Rats pretreated with BSO
and challenged with AsO had less arsenic in
the kidney and more arsenic in the skin
than rats receiving only AsO. When com-
pared to a group of rats that received only
As100, pretreatment with NAC before the
As100 dose markedly reduced arsenic con-
centration in all the tissues we studied. The
effect was more evident in the liver, skin,
and ovaries.
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Table 2. Lipid peroxidation and glutathione levels in
kidney of rats pretreated with N-acetylcysteine or
buthionine sulfoximine and subsequently challenged
with arsenic.
Treatment
Saline-saline
Saline-AsO
Saline-Asl00
NAC-saline
NAC-Asl00
BSO-saline
BSO-AsO
Peroxidation,
nmole TMP/g tissue
293.78 (71.61)
407.44(100.7)a
589.49(73.90)cd
328.83 (51.43)
505.39(42.39)k
517.11 (57.69)
560.64 (61.84)
Glutathione,
pmole/g tissue
1.99 (0.34)
1.59 (0.10)
1.13(0.23)ce
2.64 (0.35)
2.50 (0.52)
0.85 (0.26)
0.45(0.05)9
Arsenic, BSO, and NAC were given as stated in Table
1. Different from control p<0.005. Different from con-
trol p<0.025. CDifferentfrom control p<0.001. Different
from AsO p<0.05. "Different from AsO p<0.Ol.
fDifferent from NAC p<0.00l. Different from BSO
p<0.OOl. Results are mean values obtained from six
animals in each treatment group. Standard deviation is
given in parentheses. Data were evaluated by the
Student-Newman-Keuls test.
Discussion
This work showed that arsenic decreased
GSH levels and increased lipid peroxida-
tion in liver, kidney, and heart. A greater
effect was observed at 18.2 mg/kg than at
14.8 mg/kg for lipid peroxidation induc-
tion in all the three tissues. Because gluta-
thione is part of a cellular mechanism
concernedwith defense against peroxidative
attacks (19), the arsenic-induced lipid per-
oxidation can be explained by the deple-
tion of GSH. However, for these results,
we have to take into account that, in the
present work, glutathione levels were deter-
mined as nonprotein-soluble thiols.
Therefore, we cannot distinguish between
an arsenic-induced inhibition in the syn-
thesis of glutathione, an arsenic-induced
inhibition in glutathione reductase activity
(20,21), or the conjugation ofglutathione
with arsenic (22). All these mechanisms
could decrease the reduced glutathione levels
in arsenic-treated rats.
The effects of arsenic in liver of rats
pretreated with saline, NAC, or BSO
(Table 1) can be explained also by an
inverse relationship between GSH levels
and lipid peroxidation. In this tissue, the
interaction of arsenic with GSH may have
particular importance, as it has been sug-
gested that the transport of arsenic as a
GSH complex may account for the GSH
dependence ofbiliary arsenic excretion (8).
In kidney and heart, NAC pretreatment
protected the tissues against the AslOO-
induced depletion of GSH. However, the
same protection was not observed for the
induction of lipid peroxidation. AsO
depletes GSH in the kidney of BSO pre-
Table 3. Lipid peroxidation and glutathione levels in
hearttissue of rats pretreated with N-acetylcysteine or
buthionine sulfoximine and subsequently challenged
with arsenic.
Peroxidation, Glutathione,
Treatment nmole TMP/g tissue pmole/g tissue
Saline-saline 173.10(42.88) 1.08(0.11)
Saline-AsO 309.78 (32.19)a 1.03 (0.10)
Saline-AslOO 399.87 (28.41)ab 0.75 (0.12)ab
NAC-saline 185.71 (31.04) 1.17 (0.15)
NAC-AslOO 247.29(26.37)c 1.00 (0.18)
BSO-saline 217.32 (65.64) 0.98 (0.38)
BSO-AsO 364.05 (22.96) 0.85 (0.18)
Arsenic, BSO, and NAC were given as stated in Table
1. 'Different from control p<0.001. bDifferent from
AsO p<0.00l. CDifferent from NAC p<0.005.
dDifferent from BSO p<0.001. Results are mean values
obtained from six animals in each treatment group.
Standard deviation is given in parentheses. Data were
evaluated bythe Student-Newman-Keuls test.
treated rats, but an increase in lipid peroxi-
dation was not detected. In this case, BSO
decreased the tissue concentration of
arsenic, indicating that the arsenic concen-
tration may not be high enough for the
induction oflipid peroxidation.
Altogether, the results generally indi-
cated that arsenic induced an increase in
lipid peroxidation by a mechanism not
directly related to a reduction in GSH lev-
els, at least in kidney and heart (in liver,
some evidence for a negative correlation
between GSH levels and lipid peroxidation
was found). Ifthis were true, the peroxida-
tion oflipids would depend on the tissue
concentration ofarsenic.
Using the arsenic concentration found
for each kind oftreatment in the three tis-
sues (Table 4), a direct correlation was
found between arsenic concentration in the
tissues and lipid peroxidation levels: in liver
(r= 0.88, n=4), kidney (r= 0.90, n=3;
BSO-AsO results were not considered), and
heart (r=0.84, n=4). The correlations were
not statistically significant because of the
small number ofsamples; however, a clear
tendency was observed. Similar analyses were
done for the tissue concentration of arsenic
and GSH levels; in all tissues we did not
obtain statistically significant correlations.
Arsenic may induce lipid peroxidation
independently ofGSH depletion, either by
inhibiting the enzyme that catalyzes GSH-
dependent reduction of peroxides (GSH
peroxidase) or by generating higher-than-
normal levels offree radicals.
Two types ofGSH peroxidase activities
have been described (23,24): one is affected
by selenium depletion and the other is not.
A mechanism for the arsenic-induced inhi-
Table 4. Arsenic concentration in tissues of rats pre-
treated with N-acetylcysteine or buthionine sulfox-
imine and subsequently challenged with arsenic (pg/g
tissue).
Saline-
Tissue AsO
Liver 17.8(2.9)
Heart 11.2 (1.6)
Skin 4.3 (0.8)
Kidney 30.8 (3.5)
Lung 5.7 (1.4)
Ovary 17.1 (3.7)
BSO-
AsO
18.6 (2.9)
0.8(2.8)
7.6 (1.1)
17.7 (2.9)
6.1 (1.1)
19.2 (4.2)
Saline-
Asl00
22.6 (5.7)
12.4(0.9)
7.4 (1.3)
43.3 (5.1)
7.1 (1.9)
20.9 (1.8)
NAC-
AslO0
11.3 (1.6)
10.0 (2.3)
4.4 (1.2)
32.4(5.4)
5.4(1.7)
13.3 (3.0)
Arsenic, BSO, and NAC were given as stated in Table 1.
Saline-AsO versus BSO-AsO treatment: skin and kidney
p<0.001, all others not significantly different (Student's
t-test). Saline-AslOO versus NAC-AslOO: heart and
lung p<0.05; liver p<0.002; skin, kidney, and ovary
p<0.001. Heart and liver were evaluated by the Mann-
Whitney test, the others by Student's t-test. Results
are mean values obtained from six animals in each
treatment group. Standard deviation is given in paren-
theses.
bition of the selenium-dependent activity
can be postulated if we consider that
arsenic decreased the selenium levels in rats
(25). However, for the selenium-indepen-
dent activity the same rationale is not
applicable. This activity, which is associ-
ated with a GSH transferase (23,24), has
been related to arsenic resistance in cells
(26). The class of glutathione transferase
involved in the resistance to arsenic belongs
to the Pi family (26), and this specific class
ofenzyme is found in appreciable amounts
in rat kidneys (24).
As an alternative working hypothesis,
we can suggest that inorganic arsenic may
induce oxidative stress. Whether inorganic
arsenic causes cell damage through the pro-
duction ofoxygen radicals is a matter that
deserves further research. It has been
reported that oxidative damage was induced
by arsenic compounds (arsine and
dimethylated arsenics) (26-28) and that in
cells treated with inorganic arsenic, the
synthesis of heme oxygenase is increased
(this enzyme is part ofa general response to
oxydative agents in mammalian cells) (29).
It has not escaped our attention that in
rats with depleted levels of GSH (BSO-
treated rats), an arsenic shift in tissue distri-
bution was found; higher levels were
observed in skin and lower levels in kidney.
We can explain this result by assuming that
arsenic would accumulate in tissues with
available sulfhydryl groups. In this case, skin
keratins would provide those groups. It is
worth noting that arsenic causes skin cancer
and other skin diseases as a result ofchronic
exposures (30), although our study describes
acute toxicity in rats and not chronic
exposure in humans.
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This work has shown that arsenic can
increase lipid peroxidation in different tis-
sues, and initial evidence was obtained for
the mechanisms involved in this effect.
Among those mechanisms, areas that need
further research include the direct interac-
tion between arsenic and the glutathione
molecule, arsenic-induced inhibition of
GSH peroxidase activity, and the possibility
ofa direct role ofarsenic in the generation
ofoxygen radicals.
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